Polymorphisms in the Caspase Genes and the Risk of Lung Cancer  by Lee, Shin Yup et al.
ORIGINAL ARTICLE
Polymorphisms in the Caspase Genes and the Risk of
Lung Cancer
Shin Yup Lee, MD,* Yi Young Choi, MS,† Jin Eun Choi, PhD,† Min Jung Kim, BS,†
Jong-Sik Kim, BS,† Deuk Kju Jung, MS,† Hyo-Gyoung Kang, MS,† Hyo-Sung Jeon, PhD,†
Won Kee Lee, PhD,‡ Guang Jin, BS,†§ Seung Ick Cha, MD,* Chang Ho Kim, MD,*
Tae Hoon Jung, MD,* and Jae Yong Park, MD, PhD*†
Introduction: Caspases (CASPs) are important regulators and ex-
ecutioners in apoptosis pathway and play a crucial role in the
development and progression of cancer. On the basis of the inter-
actions of CASPs in the apoptotic pathway, we evaluated the
association between 11 polymorphisms of CASP3, 6, 7, 8, 9, and 10
genes and the risk of lung cancer.
Methods: The genotypes were determined in 720 patients with
lung cancer and 720 healthy controls frequency matched for age
and gender.
Results: In individual polymorphism analysis, the CASP7
rs2227310CG and CASP9 rs4645981CT were associated with
1.40-fold and 1.28-fold increased risk of lung cancer under recessive
and dominant models for the variant allele of each polymorphism,
respectively. In the case of the CASP3 77GA, subjects with the
GG genotype were at a 1.19-fold increased risk of lung cancer
compared with those with at least one variant allele. When the three
polymorphisms were combined, the risk of lung cancer increased in
a dose-dependent manner as the number of risk genotypes increased
(ptrend 0.001). Subjects with two and three risk genotypes carried
a significantly increased risk of lung cancer compared with those
with zero risk genotype (adjusted odds ratio 1.56, 95% confidence
interval  1.14–2.13, p  0.005 and adjusted odds ratio  2.54,
95% confidence interval  1.28–5.02, p  0.008, respectively).
Conclusions: These results suggest that a combined analysis of
these three CASP gene polymorphisms might better predict the risk
of lung cancer than analysis of a single polymorphism.
Key Words: Genetic Susceptibility, Lung Cancer, Polymorphism,
Caspase.
(J Thorac Oncol. 2010;5: 1152–1158)
Apoptosis is a genetically controlled process of pro-grammed cell death, which plays an important role in the
development and homeostasis of cells and tissues.1–3 Defects
in the apoptosis pathway may facilitate the accumulation of
somatic mutations, thereby increasing the risk of cancers,
including lung cancer.4,5 Caspases (CASPs), a family of
cysteine-dependent aspartate-specific proteases, are the cen-
tral engines of apoptosis that orchestrate cell death by cleav-
ing a variety of intracellular substrates that trigger cell dis-
solution.5,6 Based on their proapoptotic functions, CASPs can
be categorized into two groups; initiator CASPs and effector
CASPs. Extrinsic (CASP8 and CASP10) and intrinsic
(CASP9) initiator CASPs transmit death signals and activate
effector CASPs (CASP3, CASP6, and CASP7), which exe-
cute a coordinated program of proteolysis, resulting in the
destruction of critical cell structures.7,8
Carcinogenesis is a multistep, multigenic process;
therefore, it is unlikely that any single polymorphism would
have a dramatic effect on the risk of cancer. A pathway-based
multigenic approach, which estimates the combined effects of
a set of polymorphisms interacting in the same pathway, may
amplify the effects of individual polymorphisms and
strengthen the predictive power.9–13 We and other investiga-
tors have reported that several polymorphisms in CASP genes
are associated with risk of diverse types of human can-
cer.14–20 Most of the previous studies analyzed each individ-
ual CASP gene and thereby had obvious limitations in reveal-
ing possible interactions of multiple CASP genes. In this
study, we have added additional genotype data to the existing
data of our previous studies15,16,19,20 and analyzed the joint
effects of polymorphisms of multiple CASP genes on the risk
of lung cancer.
PATIENTS AND METHODS
Study Population
This case-control study consisted of 720 patients
with lung cancer and 720 healthy controls. The details of
the study population have been described elsewhere.15 In
brief, eligible cases included all patients newly diagnosed
with primary lung cancer between January 2001 and De-
cember 2002 at Kyungpook National University Hospital,
Daegu, Korea. There were no age, gender, histologic, or
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stage restrictions, but patients with a history of cancer
were excluded from this study. Control subjects were
randomly selected from a pool of healthy volunteers re-
striction fragment length polymorphism who visited the
general health checkup center at Kyungpook National
University Hospital during the same period. The control
subjects were frequency matched (1:1) to the cases based
on gender and age (5 years). All cases and controls were
ethnic Koreans residing in Daegu or the surrounding re-
gions. This study was approved by the Institutional Review
Board of the Kyungpook National University Hospital,
and written informed consent was obtained from each
participant.
Selection of Polymorphisms and Genotyping
In this study, 11 polymorphisms in the CASP3, 6, 7,
8, 9, and 10 genes were examined in a case-control study.
Eight polymorphisms (CASP3 77GA and rs2705897;
CASP7 rs12415607 and rs2227310; CASP8 rs3834129 and
rs3769818; and CASP9 rs4645978 and rs4645981) were
selected based on the results of our previous stud-
ies.15,16,19,20 Polymorphisms (rs13010627 and rs13006529)
of the CASP10 gene have been reported to be associated
with the risk of cutaneous melanoma and familial breast
cancer18,21; however, only rs13006529 was evaluated be-
cause rs13010627 is very rare or nonexistent in Asians.
For the CASP6 gene, we screened potentially functional
variants in the promoter region, all exons including
exon-intron boundaries (50 bp on either side of the
introns) and the 3UTR using the public database
(http://www.ncbi.nlm.nih.gov/SNP) and determined their fre-
quencies in a preliminary study consisting of 27 healthy
Koreans and 27 lung cancer cases. Of the four polymor-
phisms (rs5030516, rs2301717, rs11574697, and rs1042891)
captured from the database, rs5030516 and rs11574697 were
not detected in the preliminary study population, and thus
only the remaining 2 polymorphisms, rs2301717 and
rs1042891, were evaluated.
The CASP8 rs3834129 and rs3769818, and CASP9
rs4645978 and rs4645981 genotypes of additional cases
and controls were determined using a polymerase chain
reaction (PCR)-restriction fragment length polymorphism
assay as done in our previous studies.16,19 CASP3 77GA
and rs2705897, CASP6 rs2301717 and rs1042891, CASP7
rs12415607 and rs2227310, and CASP10 rs13006529 ge-
notypes were determined by PCR and melting-curve anal-
ysis using fluorescence-labeled hybridization probes
(LightCycler 480, Roche Diagnostic, Mannheim, Ger-
many). For quality control, the genotyping analysis was
performed blind with respect to the subjects. In addition,
approximately 10% of the samples were randomly selected
to be genotyped again by a different investigator, and the
results were 100% concordant. To confirm the genotyping
results, selected PCR-amplified DNA samples (n  10 for
each genotype) were examined by DNA sequencing, and
the results were also 100% concordant.
Statistical Analysis
The cases and controls were compared using the Student’s
t test for continuous variables and a 2 test for categorical
variables. Deviations of the genotype frequencies in the controls
from those expected under Hardy-Weinberg equilibrium were
assessed by 2 test (1 degree of freedom). Unconditional logistic
regression models were used to estimate odds ratios (ORs) and
95% confidence intervals (CIs), with adjustment for possible
confounding factors (gender as a nominal variable, and age and
pack years as continuous variables). For the gene-smoking
interaction analyses, we used three approaches to evaluate the
consistency of the results: (i) logistic regression model including
the interaction term between the genotype and smoking, (ii)
stratified analyses in specific categories of cumulative smoking
exposure, and (iii) genotype-smoking joint effects. A ho-
mogeneity test was conducted to compare the difference
between genotype-related ORs of different groups. All statis-
tical analyses were performed using SPSS version 15.0 (SPSS
Inc., Chicago, IL).
RESULTS
The demographics of the cases and controls enrolled in
this study are shown in Table 1. There were no significant
differences between the cases and controls for mean age or
gender distribution, suggesting adequate matching based on
these two variables. The case group had a higher prevalence
of current smokers than the controls (p  0.001), and the
number of pack years in smokers was significantly higher in
the cases than in the controls (39.8 18.1 versus 32.8 18.0
pack years; p  0.001). These differences were controlled in
the multivariate analyses.
The distributions of the genotypes of single nucleo-
tide polymorphisms (SNPs) of CASP3, 6, 7, 8, 9, and 10
among cases and controls are shown in Table 2. The
TABLE 1. Characteristics of the Study Population
Variables
Case-Control Study
Cases
(n  720)
Controls
(n  720) p
Age (yr) 61.3  8.8 60.6  9.3 0.12a
Sex
Male 565 (78.5) 565 (78.5) 1.000b
Female 155 (21.5) 155 (21.5)
Smoking status 0.001b
Current 463 (64.3) 331 (46.0)
Former 116 (16.1) 191 (26.5)
Never 141 (19.6) 198 (27.5)
Pack yearsc 39.8  18.1 32.8  18.0 0.001a
Histological types
Squamous cell carcinoma 320 (44.4)
Adenocarcinoma 273 (37.9)
Large cell carcinoma 12 (1.7)
Small cell carcinoma 115 (16.0)
Numbers in parentheses indicate column percentage.
a t test.
b 2 test.
c In current and former smokers.
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TABLE 2. Caspases (CASPs) Genotypes of Cases and Controls and Their Association with the Risk of Lung Cancer
Genes Genotypes
Cases, n
(%) Controls, n (%) pa
Minor Allele
Frequency
Adjusted ORb (95% CI) pbCases Controls pa
CASP3 77GA
GG 297 (41.3) 269 (37.4) 0.159 0.37 0.40 0.05 1.00
GA 317 (44.0) 322 (44.7) 0.88 (0.70–1.11) 0.274
AA 106 (14.7) 129 (17.9) 0.74 (0.54–1.02) 0.065
GAAA vs. GG 0.84 (0.68–1.05) 0.117
ptrend
c 0.060
rs2705897AC
AA 486 (67.5) 464 (64.4) 0.418 0.18 0.20 0.32 1.00
AC 206 (28.6) 229 (31.8) 0.90 (0.71–1.13) 0.365
CC 28 (3.9) 27 (3.8) 0.97 (0.55–1.69) 0.902
ptrend
c 0.458
CASP6 rs2301717CA
CC 234 (32.5) 249 (34.6) 0.677 0.43 0.42 0.39 1.00
CA 350 (48.6) 343 (47.6) 1.11 (0.87–1.41) 0.402
AA 136 (18.9) 128 (17.8) 1.19 (0.88–1.62) 0.267
ptrend
c 0.244
rs1042891CT
CC 230 (31.9) 231 (32.1) 0.798 0.43 0.43 0.76 1.00
CT 364 (50.6) 354 (49.2) 1.00 (0.78–1.27) 0.978
TT 126 (17.5) 135 (18.8) 0.94 (0.69–1.28) 0.696
ptrend
c 0.728
CASP7 rs12415607CA
CC 260 (36.1) 293 (40.7) 0.097 0.41 0.37 0.03 1.00
CA 336 (46.7) 327 (45.4) 1.12 (0.89–1.42) 0.323
AA 124 (17.2) 100 (13.9) 1.40 (1.02–1.93) 0.039
ptrend
c 0.042
rs2227310CG
CC 246 (34.2) 272 (37.8) 0.027 0.44 0.39 0.01 1.00
CG 321 (44.6) 334 (46.4) 1.07 (0.84–1.35) 0.588
GG 153 (21.3) 114 (15.8) 1.45 (1.07–1.97) 0.016
GG vs. CCCG 1.40 (1.06–1.84) 0.016
ptrend
c 0.027
CASP8 rs3834129 6N ins/del
del/del 440 (61.1) 422 (58.6) 0.616 0.22 0.24 0.40 1.00
del/del 240 (33.3) 257 (35.7) 0.91 (0.72–1.14) 0.390
del/del 40 (5.6) 41 (5.7) 0.87 (0.55–1.40) 0.576
ptrend
c 0.353
rs3769818GA
GG 358 (49.7) 373 (51.8) 0.291 0.29 0.29 0.87 1.00
GA 308 (42.8) 282 (39.2) 1.14 (0.92–1.43) 0.238
AA 54 (7.5) 65 (9.0) 0.79 (0.53–1.17) 0.239
ptrend
c 0.893
CASP9 rs4645978AG
AA 260 (36.1) 269 (37.4) 0.376 0.40 0.40 0.82 1.00
AG 349 (48.5) 325 (45.1) 1.09 (0.86–1.38) 0.477
GG 111 (15.4) 126 (17.5) 0.88 (0.64–1.21) 0.434
ptrend
c 0.656
rs4645981CT
CC 438 (60.8) 482 (66.9) 0.050 0.22 0.19 0.03 1.00
CT 251 (34.9) 209 (29.0) 1.28 (1.02–1.61) 0.037
TT 31 (4.3) 29 (4.0) 1.30 (0.76–2.21) 0.345
CTTT vs. CC 1.28 (1.03–1.60) 0.029
ptrend
c 0.039
(Continued)
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genotype distributions of the SNPs among the controls
were in Hardy–Weinberg equilibrium. The CASP3 77GA
was associated with a decreased risk of lung cancer under
dominant and additive model for variant allele at a bor-
derline significance (adjusted OR  0.84, 95% CI 
0.68–1.05, p  0.117, ptrend  0.060). When reexpressed
the CASP3 77GA-related OR in terms of risk genotype
(OR  1.0) to facilitate the comparisons in a combined
genotype analysis, the OR of the GG genotype compared
with the GA  AA genotype was 1.19 (95% CI 
0.96–1.48). The CASP7 rs12415607CA and
rs2227310CG were associated with a significantly in-
creased risk of lung cancer under a recessive model for the
variant allele of each polymorphism (adjusted OR  1.40,
95% CI  1.02–1.93, p  0.039; and adjusted OR  1.40,
95% CI  1.06–1.84, p  0.016, respectively). The
CASP9 rs4645981CT was associated with a significantly
increased risk of lung cancer under a dominant model for
variant T allele (adjusted OR  1.28, 95% CI  1.03–1.60,
p  0.029).
We extended our analysis to investigate the combined
effect of SNPs, which were associated with the risk of lung
cancer in an individual SNP analysis. The CASP7
rs12415607CA was excluded from combined genotype
analysis because it was in strong linkage disequilibrium with
the rs2227310CG. For combined genotype analysis, we
considered the CASP3 77 GG, CASP7 rs2227310 GG, and
CASP9 rs4645981 CTTT genotypes as risk genotypes. The
subjects were grouped into four categories based on the
number of risk genotypes each subject possessed. As shown
in Table 3, the frequency distribution of the combined geno-
types among the cases were significantly different from those
among the controls (Global p  0.002). The risk of lung
cancer increased in a dose-dependent manner as the number
of risk genotype increased (ptrend  0.001). Compared with
subjects with zero risk genotype, those with two and three
risk genotypes carried significantly increased risk (ad-
justed OR  1.56, 95% CI  1.14–2.13, p  0.005;
adjusted OR  2.54, 95% CI  1.28–5.02, p  0.008,
respectively). When the subjects were dichotomized into
two groups, the subjects with at least two risk genotypes
were at a 1.5-fold increased risk of lung cancer compared
with those with 0 to 1 risk genotype (adjusted OR  1.51,
95% CI  1.17–1.96, p  0.002).
We next explored the combined effect of polymor-
phisms in the six CASP genes evaluated for the risk of lung
cancer. For those genes with multiple polymorphisms as-
sayed, only one polymorphism was included in this combined
analysis, and others were excluded because of linkage dis-
equilibrium. The included polymorphisms were CASP3
77GA, CASP6 rs2301717, CASP7 rs2227310, CASP8
rs3834129, CASP9 rs4645981, and CASP10 rs13006529. For
this analysis, the variant allele at each locus was treated as a
risk allele and their combined effect evaluated by grouping
the subjects based on the number of risk alleles that each
possessed. In the case of the CASP3 77GA, the wild-type G
TABLE 2. (Continued)
Genes Genotypes
Cases, n
(%) Controls, n (%) pa
Minor Allele
Frequency
Adjusted ORb (95% CI) pbCases Controls pa
CASP10 rs13006529TA
TT 456 (63.7) 448 (62.4) 0.878 0.21 0.22 0.59 1.00
TA 219 (30.6) 227 (31.6) 0.98 (0.78–1.24) 0.860
AA 41 (5.7) 43 (6.0) 0.90 (0.57–1.43) 0.651
ptrend
c 0.680
a Two-sided 2 test for either genotype distributions or allele frequencies between the cases and controls.
b ORs (95% CIs) and corresponding p values were calculated by unconditional logistic regression analysis, adjusted for age, gender, and pack years of smoking.
c ptrend for the additive model.
CASPs, caspases; ORs, odds ratios; CI, confidence interval.
TABLE 3. Combined Effect of Multiple Polymorphisms in
CASP Genes on the Risk of Lung Cancer
Cases,
No. (%)
Controls,
No. (%)
Adjusted ORa
(95% CI) pa
No. of risk
genotypesb
0 204 (28.3) 246 (34.2) 1.00
1 329 (45.7) 341 (47.4) 1.17 (0.91–1.50) 0.214
2 158 (21.9) 119 (16.5) 1.56 (1.14–2.13) 0.005c
3 29 (4.0) 14 (1.9) 2.54 (1.28–5.02) 0.008d
Global p 0.002
ptrend 0.001
0–1 533 (74.0) 587 (81.5) 1.00
2–3 187 (26.0) 133 (18.5) 1.51 (1.17–1.96) 0.002
No. of adverse
allelese
0–3 251 (35.1) 287 (40.0) 1.00
4 162 (22.6) 161 (22.5) 1.21 (0.91–1.61) 0.189
5 140 (19.6) 122 (17.0) 1.37 (1.01–1.85) 0.045
6–10 163 (22.8) 147 (20.5) 1.28 (0.96–1.71) 0.089
Global p 0.215
ptrend 0.045
a Adjusted for age, gender, and pack years of smoking.
b Risk genotypes: CASP3 77 GG, CASP7 rs2227310 GG, and CASP9 rs4645981
CTTT.
Bonferroni corrected p values (pc): 0.015
c and 0.024.d
e Adverse alleles: variant alleles of CASP6 rs2301717, CASP7 rs2227310, CASP8
rs3834129, CASP9 rs4645981, and CASP10 rs13006529 and wild-type allele of CASP3
77GA.
CASPs, caspases; ORs, odds ratios; CI, confidence interval.
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allele was treated as a risk allele because the variant A allele
was associated with a reduced risk of lung cancer. The
number of risk alleles for each individual ranged from 0 to
10. The number of subjects with 0 to 2 and 7 to 10 risk alleles
was small, and thus, subjects were divided into four groups as
follows: 0 to 3, 4, 5, or 6 to 10 risk alleles. Compared with
individuals with 0 to 3 risk alleles, the risk of lung cancer
increased as the number of risk alleles increased (ptrend 
0.045, Table 3).
The effect of combined genotypes on lung cancer risk
was examined further after stratifying the subjects according
to age, smoking status, and tumor histology (Table 4). Sub-
jects with two to three risk genotypes were compared with
those with 0 to 1 risk genotype with respect to the risk of lung
cancer. The effect of combined genotype on the risk of lung
cancer was significant in younger individuals (adjusted OR
1.89, 95% CI  1.28–2.78, p  0.001) and ever smokers
(adjusted OR  1.73, 95% CI  1.28–2.33, p  0.001) but
not in older individuals and never smokers. When stratified
according to histology, the risk of lung cancer was not
different between non-small cell lung cancer and small cell
lung cancer.
In addition to the stratification analyses, the joint effect
of combined genotypes and smoking on the risk of lung
cancer was also investigated to assess a potential gene-
smoking interaction (Table 5). The group of heavy smokers
with two or more risk genotypes carried the highest risk of
lung cancer compared with the group of never smokers with
0 to 1 risk genotype (adjusted OR  6.92, 95% CI 
3.95–12.12, p  0.001). However, we did not find a signif-
icant interaction between combined genotypes and smoking
(p  0.11 for the interaction term).
DISCUSSION
Several studies have found associations between ge-
netic polymorphisms in some CASP genes such as CASP9
and CASP10 and the risk of certain cancers, including lung
cancer, and the results are encouraging.14–18 However,
most of the previous studies were designed to analyze an
individual gene, which obviously have limitations to elu-
cidate the effects of entire CASP genes. To comprehen-
sively evaluate the roles of CASP gene polymorphisms in
the development of lung cancer, we examined individual
and joint effects of 11 potentially functional polymor-
phisms in six major CASP genes. In this study, three
polymorphisms (CASP3 77GA, CASP7 rs2227310CG,
and CASP9 rs4645981CT) were associated with the risk
of lung cancer. More importantly, the combined analysis
of these three polymorphisms showed an increased risk of
lung cancer with an increasing number of adverse geno-
types. These results were in line with the concept that the
estimation of the combined effects of a set of polymor-
phisms interacting in the same pathway could amplify the
effects of individual polymorphisms and have better reso-
lution in risk prediction compared with analysis of each
single polymorphism. This is the first study evaluating the
effect of combined genotypes of multiple CASP genes on
the risk of lung cancer.
TABLE 4. Association Between Combined CASP3, 7, and 9 Genotypes and Lung Cancer According to Age, Smoking Status,
and Histological Types of Lung Cancer
No. of Risk Genotypesa
Adjusted OR (95% CI) p pH
Cases (n  720) Controls (n  720)
0–1 2–3 0–1 2–3
Age (yr)
62 248 (74.7) 84 (25.3) 320 (85.1) 56 (14.9) 1.89 (1.28–2.78)b 0.001 0.110
62 285 (73.5) 103 (26.5) 267 (77.6) 77 (22.4) 1.24 (0.87–1.75)b 0.233
Smoking status
Never 105 (74.5) 36 (25.5) 152 (76.8) 46 (23.2) 1.08 (0.65–1.80)c 0.768 0.118
Ever 428 (73.9) 151 (26.1) 435 (83.3) 87 (16.7) 1.73 (1.28–2.33)c 0.001
Histology
NSCLC 448 (74.0) 157 (26.0) 587 (81.5) 133 (18.5) 1.52 (1.16–1.98)d 0.002 1.000
SCLC 85 (73.9) 30 (26.1) 587 (81.5) 133 (18.5) 1.52 (0.95–2.44)d 0.083
a Risk genotypes: CASP3 77 GG, CASP7 rs2227310 GG, and CASP9 rs4645981 CTTT.
OR, 95% confidence intervals (CIs) and their corresponding p values were calculated by unconditional logistic regression analysis, adjusted b for sex, pack years of smoking,
c for age and sex, d for age, sex, pack years of smoking.
pH, test for homogeneity; CASPs, caspases; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; OR, odds ratios; CI, confidence interval.
TABLE 5. Interaction of Combined CASP3, 7, and 9
Genotypes with Tobacco Smoking on the Risk of Lung
Cancer
Smoking Status
No. of Risk Genotype
0–1 OR (95% CI)a 2–3 OR (95% CI)a
Never smoker 105/152b 1.00 (reference) 36/46 1.08 (0.65–1.80)
Smoker
38 pack years 177/272 1.79 (1.16–2.76) 61/48 3.54 (2.05–6.12)
38 pack years 251/163 4.61 (2.91–7.30) 90/39 6.92 (3.95–12.12)
p for interaction term  0.11 (when categorized into never smoker and smoker).
a ORs (95% CIs) and corresponding p values were calculated by unconditional
logistic regression, with zero risk genotype in never smokers as reference group and
adjusted for age and gender.
b Cases no./controls no.
CASPs, caspases; OR, odds ratios; CI, confidence interval.
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The most significant finding of this study is that
combined analysis of multiple polymorphisms in CASP
genes had a much higher potential value in terms of
unraveling lung cancer related polymorphisms. Although
the CASP3 77 GG, CASP7 rs2227310 GG, and CASP9
rs4645981 CTTT genotypes were associated with 1.19-
fold, 1.40-fold, and 1.28-fold increased risk of lung cancer
in individual polymorphism analysis, respectively, the im-
pact of any individual polymorphism on the risk of lung
cancer would be minimal considering the borderline CIs
and multiple comparisons. However, when these three
polymorphisms were combined, the risk of lung cancer
was increased as the number of bad genotypes increased
(ptrend  0.001). The presence of two and three bad
genotypes was associated with 1.56-fold and 2.54-fold
increased risk compared with subjects with zero risk ge-
notype, respectively. These results indicate that the ad-
verse genotypes of the three polymorphisms additively
increase the risk of lung cancer. In addition, this finding
indicates that a combined analysis of multiple CASP gene
polymorphisms may have a greater power to identify
high-risk populations compared with an analysis of a
single polymorphism.
Another interesting finding of this study is that the
effect of combined genotypes on the risk of lung cancer
was modified by smoking. In this study, the presence of
two or more risk genotypes was associated with a signif-
icantly increased risk of lung cancer only in ever smokers,
suggesting that the genotype effect is modified by smok-
ing. In addition, the results of joint effect analysis sug-
gested that the interaction exists between combined CASP
genotypes and smoking because the joint effect of two
exposures is greater than the product of the individual
effects.22 This interaction was not statistically significant
in multivariate logistic regression analysis (p  0.11 for
the interaction term), which is likely due to the limited
study power with reduced sample size in the subgroup.
Additional studies powered by a greater number of sub-
jects might be needed to confirm the potential gene-
smoking interaction.23
Our findings were in agreement with those of previ-
ous studies.15,16,20 It was predicted that the CASP3 77 G to
A change would create a putative transcription factor
binding site to increase the efficiency of CASP3 transcrip-
tion.20 Accordingly, the CASP3 77G allele is likely to be
associated with an increased risk of lung cancer compared
with A allele. In the case of the CASP7 rs2227310CG, it
is located in the C-terminal end of the CASP7 gene and
produces an E to D change in different amino acid posi-
tions of non- isoforms and a S244T change in the isoform
 of the CASP7. Although the effect of the SNP on protein
expression or function remains to be elucidated, it was
predicted that the E-to-D change may possibly be damag-
ing the alpha isoform,15 suggesting that the rs2227310 may
be a functional SNP. Alternatively, the association be-
tween the rs2227310CG and lung cancer may be second-
ary to linkage disequilibrium with a functional variant in
the CASP7 gene, such as the rs2227309GA, which pro-
duces a K249R change in the  isoform. The CASP9
rs4645981T allele has been reported to be associated with
a decreased promoter activity.16 Therefore, it could be
inferred that the CASP9 rs4645981T allele may lead to a
lower CASP9 production and decreased apoptotic capac-
ity; and thus, the CASP9 rs4645981 CTTT genotype is
likely to be associated with an increased lung cancer risk.
These results indicate that the adverse genotypes of
the three polymorphisms additively increase the risk of
lung cancer. In addition, this finding indicates that a
combined analysis of multiple CASP gene polymorphisms
may have a greater power to identify high-risk populations
compared with analysis of a single polymorphism. Al-
though the combined effect of multiple apoptotic gene
polymorphisms on apoptotic capacity has not been studied,
the observed gene-dosage effect of CASP gene polymor-
phisms on the risk of lung cancer may be due to that
individual’s apoptotic capacity is determined by the col-
lective effect of multiple CASPs. This explanation is
supported by several studies that have reported similar
dose-dependent relationships between DNA repair gene
polymorphisms and DNA repair capacity.24,25
Recently, Ulybina et al.26 investigated the associa-
tions of nonsynonymous coding polymorphisms of apopto-
tic genes, including CASPs with lung cancer in European
populations. In their study, three polymorphisms, includ-
ing the CASP5 rs523104 (V318L) and CASP8 rs1045485
(H302D), showed promising associations in a case-control
study consisting of light- or nonsmoking young patients
and elderly tumor-free heavy smokers, although these
associations did not reach the level of statistical signifi-
cance in a validation study. In this study, we focused only
on major initiator and effector CASP genes (CASP3, 6, and
7, and CASP8-10). CASP8 rs1045485 was not evaluated
because it was not detected in a preliminary study of 90
patients with lung cancer and 91 healthy controls as
described previously.19
In conclusion, we demonstrated an additive effect of
CASP3 77GA, CASP7 rs2227310CG and CASP9
rs4645981CT on the risk of lung cancer in a Korean
population. Additional studies with a larger sample size
and in different ethnic groups are required to confirm our
findings.
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